Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.53 |
| ▸ | TK2 | O00142 | 5/20 | 0.46 |
| ▸ | TK1 | P04183 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475148 | 1.00 | RNASE1 (0.53) | RNASE1TK2TK1 | |
| SCHEMBL30976656 | 1.00 | RNASE1 (0.53) | RNASE1TK2TK1 | |
| SCHEMBL5489355 | 1.00 | RNASE1 (0.53) | RNASE1TK2TK1 | |
| SCHEMBL5475154 | 1.00 | RNASE1 (0.53) | RNASE1TK2TK1 | |
| SCHEMBL6251494 | 0.94 | RNASE1 (0.48) | RNASE1TK2TK1 | |
| SCHEMBL6251497 | 0.94 | RNASE1 (0.48) | RNASE1TK2TK1 | |
| SCHEMBL9810769 | 0.90 | TK1 (0.43) | RNASE1TK1 | |
| SCHEMBL9810774 | 0.90 | TK1 (0.43) | RNASE1TK1 | |
| SCHEMBL6339812 | 0.90 | RNASE1 (0.50) | RNASE1TK2TK1 | |
| SCHEMBL6339815 | 0.90 | RNASE1 (0.50) | RNASE1TK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | METKINEN OY (FI) | 2007-03-22 | — | — | US | disclosed |
| US-6891033-B2 | Chemical intermediates such as 3-N-Boc-1-(5-O-(4,4'-dimethoxytrityl)-3-O-nosyl-2-deoxy-beta-D -lyxofuranosyl)thymine; use of final compound in positron emission tomography (PET) | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2005-05-10 | — | — | US | disclosed |
| US-20040110720-A1 | Labelling compounds for the simple synthesis of 3'-(18f)fluoro-3'-deoxy thymidine and a method for the production thereof | DEUTCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES O'FFENTLICHEN RECHTS (DE) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | DUT, UNG, GALE | RNASE1 101/4885TK2 171/4885TK1 71/4885 |
| US-20040110720-A1 | Labelling compounds for the simple synthesis of 3'-(18f)fluoro-3'-deoxy thymidine and a method for the production thereof | TK1, TYMS, TYMP | RNASE1 873/4885TK2 16/4885TK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.